期刊文献+

miR-505慢病毒表达载体的构建

下载PDF
导出
摘要 目的:构建携带增强绿色荧光蛋白(enhanced green fluorescent protein,EGFP)和miR-505基因的慢病毒载体。方法:采用PCR方法从pcDNATM6.2-GW/EmGFP-miR-505表达载体质粒扩增出miR-505 shRNA基因编码区173bp、175、171bp片段,通过限制性酶切、T4DNA连接酶连接,分别将miR-505 shRNA基因插入慢病毒表达载体FUGW与L26Fsy(1.1)GW中,构建成重组载体FUGW-miR-505-3p/5p/nc与Fsy-miR-505-3p/5p/nc。脂质体介导下将慢病毒重组载体转染至HEK 293T细胞,通过EGFP观察转染效率,RT-PCR方法检测miR-505的表达量。结果:荧光显微镜下观测到HEK 293T细胞转染后有较强绿色荧光;RT-PCR显示转染FUGW-miR-505-3p/5p与Fsy-miR-505-3p/5p的HEK 293T细胞中对应miR-505-3p/5p明显升高。结论:成功构建带有EGFP和miR-505-3p/5p/nc shRNA基因的慢病毒表达载体。
出处 《吉林农业(下半月)》 2014年第2期24-26,共3页
  • 相关文献

参考文献14

  • 1Doench J G,Sharp P A.Specificity of microRNA target se- lection in translational[J].Genes Dev,2004,18(5):504-511.
  • 2Brennecke J,Stark A,1Lussell IL B,et al.Principles of microR- NA-target recognition[J].PLoS Biol,2005,3(3):e85-e85.
  • 3Lewis B P,Burge C B,Bartel D P.Conserved seed pairing, o(ten flanked by adenosines,indicates that thousands od human genes are microRNA targets[J].Cell,2005,120(1):18-20.
  • 4Bartel DP.MicroRNAs:genomics,biogenesis,mechanism,and function[J].Cell,2004, l 16 (2) :281-297.
  • 5Victor Ambros,朱万渠.MicroRNAs与疾病和发育[J].生命科学,2010,22(3):229-231. 被引量:7
  • 6Cockrell AS,Kaffi T.Gene delivery by lentivirus vectors[J].Mol Biotechnol,2007,36(3): 184-204.
  • 7Dittgen T,Nimmerjahn A,Komai S,Licznerski P,Waters J, Margrie TW,Helmchen F,Denk W, Brecht M,and Osten P. Lentivirus-based genetic manipulations of comical neurons and their optical and electrophysiolog'ical monitoring invivo [J].Proc.Natl ac sci USA,20(-14,101 (18):206-211.
  • 8赵慧,郑文岭,崔东,马文丽.泛素启动子的研究进展[J].广东医学,2003,24(12):1376-1377. 被引量:3
  • 9Verduci,L,Simili M,Rizzo M,Mercatanti A,Evangelista M et al. MicroP,,NA (miI~NA)-mediated l,ateraction between Leukemia/ Lymphoma-related Factor (LRF) and Alternative splic- ing filctor/splicing factor 2 (ASF/SF2) affects mouse embryonic fi- broblast senescence and apoptosis [J].Biol Chem,2010,285 (39): 55/-563.
  • 10Karni R,Hippo Y,Lowe SW,Krainer AR.The splicing-fac- tor oncoprotein SF2/ASF activates mTORCl.[J].Proc Nail Acad Sci USA.,21 )1)8,105 (40): 15323 - 15327.

二级参考文献11

  • 1[1]Conaway RC, Brower CS, Conaway JW, et al. Emerging roles of ubiquitin in transcription regulation. Science, 2002, 296 (7): 1254
  • 2[2]Nenoi M, Mita K, Ichimura S, et al. Heterogeneous structure of the polyubiquitin gene UbC of HeLa S3 cells. Gene, 1996, 175: 179
  • 3[3]Miao CH, Ohashi K, Patijin GA, et al. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor Ⅸ gene expression in vivo but not in vitro. Mol Ther, 2000,1(6): 522
  • 4[4]Jallat S, Perraud F, Dalemans W, et al. Characterization of recombinant human factor Ⅸ expressed in transgenic mice and in derived trans-immortalized hepatic cell lines. EMBO J, 1990, 9: 3295
  • 5[5]III CR, Yang CQ, Bielingmaier SM, et al. Optimization of the human factor Ⅷ complementary DNA expression plasmid for gene therapy of hemophilia A. Blood Coagul Fibrinolysis, 1997, 8(Suppl 2): 523
  • 6[6]Ciechanover A, Orian A, Schwart ZA. Ubiquitin-mediated proteolysis:biological regulation via destruction. Bioessays, 2000, 22: 442
  • 7[7]Tousignant JD, Grates AL, Ingram LA, et al. Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid: plasmid DNA complexes in mice. Hum Gene Ther, 2000,11: 2493
  • 8[8]Yew NS, Przybylska M, Ziegler RJ, et al. High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter. Mol Ther, 2001, 4(1): 75
  • 9[9]Schorpp M, Jāger R, Schellander K, et al. The human ubiquitin C promoter directs high ubiquitous expression of transgenes in mice. Nucleic Acids Res, 1996,24(9):1787
  • 10[10]Balague C, Zhou J, Dai Y, et al. Sustained high-level expression of full-length human factor Ⅷ and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector.Blood, 2000,95:820

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部